441 related articles for article (PubMed ID: 23973099)
41. Neuroforaminal chondrocyte metaplasia and clustering associated with recombinant bone morphogenetic protein-2 usage in transforaminal lumbar interbody fusion.
Christensen TJ; Annis P; Hohl JB; Patel AA
Spine J; 2014 Jun; 14(6):e23-8. PubMed ID: 24291359
[TBL] [Abstract][Full Text] [Related]
42. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions.
Vaidya R; Sethi A; Bartol S; Jacobson M; Coe C; Craig JG
J Spinal Disord Tech; 2008 Dec; 21(8):557-62. PubMed ID: 19057248
[TBL] [Abstract][Full Text] [Related]
43. Adverse Events With the Use of rhBMP-2 in Thoracolumbar and Lumbar Spine Fusions: A 9-Year Institutional Analysis.
Lubelski D; Abdullah KG; Steinmetz MP; Alvin MD; Nowacki AS; Chakka S; Benzel EC; Mroz TE
J Spinal Disord Tech; 2015 Jun; 28(5):E277-83. PubMed ID: 23429306
[TBL] [Abstract][Full Text] [Related]
44. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2).
Wong DA; Kumar A; Jatana S; Ghiselli G; Wong K
Spine J; 2008; 8(6):1011-8. PubMed ID: 18037352
[TBL] [Abstract][Full Text] [Related]
45. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age.
Glassman SD; Carreon LY; Djurasovic M; Campbell MJ; Puno RM; Johnson JR; Dimar JR
Spine (Phila Pa 1976); 2008 Dec; 33(26):2843-9. PubMed ID: 19092613
[TBL] [Abstract][Full Text] [Related]
46. Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up.
Hamilton DK; Smith JS; Reames DL; Williams BJ; Chernavvsky DR; Shaffrey CI
Neurosurgery; 2011 Jul; 69(1):103-11; discussion 111. PubMed ID: 21368688
[TBL] [Abstract][Full Text] [Related]
47. Instrumented one and two level posterolateral fusions with recombinant human bone morphogenetic protein-2 and allograft: a computed tomography study.
Stambough JL; Clouse EK; Stambough JB
Spine (Phila Pa 1976); 2010 Jan; 35(1):124-9. PubMed ID: 20042965
[TBL] [Abstract][Full Text] [Related]
48. Multiple-day drainage when using bone morphogenic protein for long-segment thoracolumbar fusions is associated with low rates of wound complications.
Saulle D; Fu KM; Shaffrey CI; Smith JS
World Neurosurg; 2013; 80(1-2):204-7. PubMed ID: 22929109
[TBL] [Abstract][Full Text] [Related]
49. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study.
Vaccaro AR; Whang PG; Patel T; Phillips FM; Anderson DG; Albert TJ; Hilibrand AS; Brower RS; Kurd MF; Appannagari A; Patel M; Fischgrund JS
Spine J; 2008; 8(3):457-65. PubMed ID: 17588821
[TBL] [Abstract][Full Text] [Related]
50. Symptomatic ectopic intracanal ossification after transforaminal lumbar interbody fusion with rhBMP-2.
Lehman RA; Kang DG
Spine J; 2012 Jun; 12(6):530-1. PubMed ID: 22682741
[No Abstract] [Full Text] [Related]
51. Quantitative assessment of retrograde ejaculation using semen analysis, comparison with a standardized qualitative questionnaire, and investigating the impact of rhBMP-2.
Tepper G; Rabbani R; Yousefzadeh M; Prince D
Spine (Phila Pa 1976); 2013 May; 38(10):841-5. PubMed ID: 23403551
[TBL] [Abstract][Full Text] [Related]
52. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
Boden SD; Kang J; Sandhu H; Heller JG
Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
[TBL] [Abstract][Full Text] [Related]
53. Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases.
Balseiro S; Nottmeier EW
Spine J; 2010 Jul; 10(7):e6-e10. PubMed ID: 20488766
[TBL] [Abstract][Full Text] [Related]
54. Formation of painful seroma and edema after the use of recombinant human bone morphogenetic protein-2 in posterolateral lumbar spine fusions.
Garrett MP; Kakarla UK; Porter RW; Sonntag VK
Neurosurgery; 2010 Jun; 66(6):1044-9; discussion 1049. PubMed ID: 20495420
[TBL] [Abstract][Full Text] [Related]
55. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.
Faundez A; Tournier C; Garcia M; Aunoble S; Le Huec JC
Int Orthop; 2016 Jun; 40(6):1309-19. PubMed ID: 26961193
[TBL] [Abstract][Full Text] [Related]
56. rhBMP-2 enhancement of posterolateral spinal fusion in a rabbit model in the presence of concurrently administered doxorubicin.
Singh K; Smucker JD; Ugbo JL; Tortolani PJ; Tsai L; Fei Q; Kuh S; Rumi M; Heller JG; Boden SD; Yoon ST
Spine J; 2007; 7(3):326-31. PubMed ID: 17482116
[TBL] [Abstract][Full Text] [Related]
57. A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions.
Vaccaro AR; Patel T; Fischgrund J; Anderson DG; Truumees E; Herkowitz H; Phillips F; Hilibrand A; Albert TJ
Eur Spine J; 2003 Oct; 12(5):495-500. PubMed ID: 12908103
[TBL] [Abstract][Full Text] [Related]
58. The effect of platelet-rich plasma and bone marrow on murine posterolateral lumbar spine arthrodesis with bone morphogenetic protein.
Rao RD; Gourab K; Bagaria VB; Shidham VB; Metkar U; Cooley BC
J Bone Joint Surg Am; 2009 May; 91(5):1199-206. PubMed ID: 19411469
[TBL] [Abstract][Full Text] [Related]
59. Occipitocervical fusion using recombinant human bone morphogenetic protein-2: adverse effects due to tissue swelling and seroma.
Shahlaie K; Kim KD
Spine (Phila Pa 1976); 2008 Oct; 33(21):2361-6. PubMed ID: 18827703
[TBL] [Abstract][Full Text] [Related]
60. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine.
Smucker JD; Rhee JM; Singh K; Yoon ST; Heller JG
Spine (Phila Pa 1976); 2006 Nov; 31(24):2813-9. PubMed ID: 17108835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
